{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:30:12Z","timestamp":1786973412008,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bulcan.2024.07.012","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T08:46:42Z","timestamp":1730882802000},"page":"1208-1224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Les lymphomes cutan\u00e9s T"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6367-4227","authenticated-orcid":false,"given":"Michel","family":"D\u2019Incan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2024.07.012_bib0335","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0340","first-page":"2","article-title":"Recent advances in cutaneous lymphoma epidemiology","volume":"1","author":"Dobos","year":"2022","journal-title":"Press Med"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0345","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/bjd.19644","article-title":"Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Registry","volume":"184","author":"Dobos","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0350","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/ijd.16098","article-title":"Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management","volume":"61","author":"Khotari","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0355","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/PAS.0b013e318275d1a2","article-title":"TCR-gamma expression in primary cutaneous T-cell lymphomas","volume":"37","author":"Rodriguez-Pinilla","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0360","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1309\/QH6XLRF3MVUF2M8M","article-title":"Bone marrow histopathologic and molecular staging in epidermotropic T-cell lymphomas","volume":"119","author":"Sibaud","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0365","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjd.19303","article-title":"Should we be imaging lymph nodes at initial diagnostic of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study","volume":"184","author":"Hodak","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0370","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases","volume":"96","author":"Vergier","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaad.2016.03.009","article-title":"New insights into folliculotropic mycosis fungoides (FMF): a single-center experience","volume":"75","author":"Hodak","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0380","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjd.21699","article-title":"Granulomatous slack skin: clinical characteristics, prognosis and response to therapy. A study from the Cutaneous Lymphoma French Study Group","volume":"187","author":"Battesti","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jdv.15931","article-title":"Lymphomatoid papulosis: an update and review","volume":"34","author":"Martinez-Cabriales","year":"2020","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0390","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/PAS.0b013e318282d01e","article-title":"Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis","volume":"37","author":"Karai","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0395","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/PAS.0000000000002200","article-title":"Lymphomatoid papulosis with T-cell receptor gamma-delta expression. A clinicopathologic case-series of 26 patients of an underrecognized immunophenotypic variant of lymphomatoid papulosis","volume":"48","author":"Mark","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0400","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1634\/theoncologist.2015-0242","article-title":"Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis","volume":"21","author":"Cordel","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0405","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jdv.16065","article-title":"Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis","volume":"34","author":"Melchers","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0410","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/his.13794","article-title":"Biphasic pathological pattern in transformed mycosis fungoides not associated with DUSP22-IRF4 translocation","volume":"74","author":"Daragon","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0415","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/modpathol.2010.225","article-title":"Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies","volume":"24","author":"Wada","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0420","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0425","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjd.19495","article-title":"Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas","volume":"184","author":"D\u2019Incan","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0430","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0435","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2023.10.007","article-title":"Bridging the specialty gap: update on primary cutaneous lymphomas","volume":"90","author":"Olsen","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0440","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/bjd.18481","article-title":"Revisiting the initial diagnosis and blood staging of mycosis fungoides and S\u00e9zary syndrome with the KIR3DL2 marker","volume":"182","author":"Roelens","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0445","doi-asserted-by":"crossref","first-page":"e0173171","DOI":"10.1371\/journal.pone.0173171","article-title":"TP53 alterations in primary and secondary Sezary syndrome: a diagnostic tool for the assessment of malignancy in patients with erythroderma","volume":"12","author":"Gros","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0450","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0455","first-page":"1058","article-title":"HAVCR2 mutations are associated with severe hemophagocytis syndrome in sub-cutaneous panniculitis-like T-cell lymphoma","volume":"135","author":"Sonigo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0460","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1080\/10428194.2021.1901098","article-title":"Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes","volume":"62","author":"Machan","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0465","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12788\/j.sder.2018.015","article-title":"NK\/T-cell lymphoma, nasal type, \u03b3\u03b4 T-cell lymphoma, and CD8-positive epidermotropic T-cell lymphoma-clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Geller","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0470","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/PAS.0000000000000768","article-title":"Primary cutaneous T-cell lymphomas showing gamma-delta phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous \u03b3\u03b4 T-Cell lymphomas","volume":"41","author":"Merrill","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0475","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","article-title":"Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma","volume":"101","author":"Toro","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0480","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cup.12091","article-title":"Indolent course of cutaneous gamma-delta T-cell lymphoma","volume":"40","author":"Endly","year":"2013","journal-title":"J Cut Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0485","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.clindermatol.2023.09.008","article-title":"Panniculitic primary cutaneous gamma delta T-cell lymphoma with concomitant features of autoimmune disease emphasizing a pathophysiologic continuum of lupus profundus with the panniculitic T cell lymphomas","volume":"41","author":"Magro","year":"2023","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0490","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0002-9440(10)65144-9","article-title":"Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior","volume":"155","author":"Berti","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0495","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood.2021012536","article-title":"Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0500","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2011.07.043","article-title":"Primary cutaneous aggressive epidermotropic CD81 T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation","volume":"67","author":"Nofal","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0505","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.clindermatol.2023.09.002","article-title":"Primary cutaneous acral CD8-positive T-cell lympho proliferative disorder: a clinical and histologic retrospective cohort study","volume":"41","author":"Stephan","year":"2023","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0510","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1097\/PAS.0b013e318068b527","article-title":"Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?","volume":"31","author":"Petrella","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0515","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjd.20973","article-title":"Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lympho proliferations. Results of an EORTC Cutaneous Lymphoma Group Workshop","volume":"186","author":"Kempf","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0520","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/PAS.0000000000001470","article-title":"Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorders: a clinical, pathologic, and molecular Study of 60 Cases presenting with a single lesion. A multicenter study of the French Cutaneous Lymphoma Study Group","volume":"44","author":"Beltzung","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0525","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1038\/s41598-023-33031-3","article-title":"Deciphering the spectrum of cutaneous lymphomas expressing TFH markers","volume":"13","author":"Donzel","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0530","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjd.21791","article-title":"Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study","volume":"187","author":"Wang","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0535","doi-asserted-by":"crossref","first-page":"1298296","DOI":"10.3389\/fonc.2023.1298296","article-title":"Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation","volume":"13","author":"Alberti-Violetti","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0540","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1080\/10428194.2023.2254435","article-title":"Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoides","volume":"64","author":"Pena","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0545","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2340\/00015555-3124","article-title":"Low versus middle-dose total skin electron beam therapy for mycosis fungoides: an efficiency-based retrospective survey of skin response","volume":"99","author":"Taverniers","year":"2019","journal-title":"Acat Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0550","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","article-title":"Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series","volume":"28","author":"Lewis","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0555","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/pharmaceutics15051328","article-title":"An update on recent advances of photodynamic therapy for primary cutaneous lymphomas","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0560","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0565","doi-asserted-by":"crossref","first-page":"adv00746","DOI":"10.2340\/actadv.v102.718","article-title":"Real-life use of bexarotene for T-cell cutaneous Lymphoma management: efficacy and tolerance with low doses","volume":"102","author":"Rouanet","year":"2022","journal-title":"Acta Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0570","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/jdv.16567","article-title":"Monotherapy and combinasion therapy with acitretin for mycosis fungoides: results of a multicentre retrospective study","volume":"34","author":"Nikolaou","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0575","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3390\/cancers16050861","article-title":"JAK Inhibitors in cutaneous T-cell lymphoma: friend or foe? A systematic review of the published literature","volume":"16","author":"Vahabi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0580","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/bjd\/ljae152","article-title":"Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides\/S\u00e9zary syndrome using Time to Next Treatment as a measure of clinical benefit: an EORTC CLTG study","volume":"191","author":"Mitsunaga","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0585","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/jdv.16890","article-title":"European Dermatology Forum: updated guidelines on the use of extracorporeal photopheresis 2020","volume":"34","author":"Knobler","year":"2020","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0590","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"De Masson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0595","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs. physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0600","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/his.14660","article-title":"Intraindividual variability of CD30 expression in mycosis fungoides: implications for diagnostic evaluation and therapy","volume":"81","author":"Mitteldorf","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0605","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: a multicentre, retrospective, real-world French study","volume":"37","author":"Beylot-Barry","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0610","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jdv.19801","article-title":"Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: a systematic review","volume":"38","author":"Avallone","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0615","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0620","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clml.2013.02.020","article-title":"Duration of response in cutaneous T-cell lymphoma patients with denileukin diftitox: results from 3 phase III studies","volume":"13","author":"Duvic","year":"2013","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0625","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S\u00e9zary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0630","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2133.2009.09230.x","article-title":"Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases","volume":"161","author":"Jidar","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0635","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u00a0\u2013\u00a0Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0640","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0645","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1182\/bloodadvances.2023011041","article-title":"International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies","volume":"14","author":"Campbell","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0650","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/jamadermatol.2018.5905","article-title":"Evaluation of low-dose, low-frequency oral Psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: a randomized clinical trial","volume":"155","author":"Vieyra-Garcia","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0655","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.07.012_bib0330","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2023.08.015","article-title":"Descriptive analysis and factors influencing survival in patients with primary cutaneous gamma-delta T cell lymphoma. A retrospective National Cancer Database study","volume":"23","author":"Kumar","year":"2023","journal-title":"Clin Lymph Myeloma Leukemia"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:56:45Z","timestamp":1758301005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124003370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0007455124003370"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.07.012","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les lymphomes cutan\u00e9s T","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}